Welcome to our dedicated page for Veeva Sys news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Sys stock.
Veeva Systems (VEEV) delivers cloud solutions transforming life sciences operations through CRM, quality management, and regulatory compliance tools. This news hub provides investors and industry professionals with essential updates on the company's strategic developments.
Access real-time announcements including quarterly earnings, product innovations, and strategic partnerships. Our curated collection features press releases about Veeva Vault implementations, AI-enhanced CRM capabilities, and compliance milestones critical for pharmaceutical and biotech organizations.
Bookmark this page for verified updates on clinical trial management advancements, quality control system upgrades, and regulatory submissions supported by Veeva's industry-specific platforms. Stay informed about developments impacting life sciences technology landscapes through our neutral, comprehensive reporting.
Veeva Systems (NYSE: VEEV) announced that Samsung Biologics has implemented Veeva Vault QMS to enhance its quality management processes. This integration complements Samsung's use of Veeva Vault QualityDocs, streamlining document control for improved visibility and compliance. With this upgrade, Samsung Biologics strengthens its quality processes across global operations, responding to evolving regulatory standards. James Choi, CIO of Samsung Biologics, emphasized the importance of unified quality management for effective manufacturing, highlighting the strategic partnership with Veeva to drive innovation.
Veeva Systems (NYSE: VEEV) announced that Simbec-Orion, a contract research organization, will implement the Veeva Vault CTMS and Veeva Vault eTMF to enhance clinical trial operations. This adoption aims to digitize workflows and improve real-time data sharing, boosting trial efficiency. Simbec-Orion's CIO noted that Veeva's solutions provide a digital foundation for effective clinical trials. The integration allows for better collaboration and compliance, ultimately accelerating trial execution while maintaining high-quality data for sponsors.
Veeva Systems (NYSE: VEEV) announced that GenesisCare Clinical CRO has integrated Veeva Vault eTMF, CTMS, and Payments into its operations to enhance trial processes globally. This partnership allows GenesisCare to utilize a secure cloud platform for streamlined drug development, enhancing efficiency in managing clinical studies. The integration aims to simplify data sharing, document management, and payment processes, contributing to quicker and more effective trial execution as GenesisCare expands its services.
Veeva Systems reported impressive growth in its fiscal third quarter ending October 31, 2020, with total revenues reaching $377.5 million, a 34% increase year-over-year. Subscription services revenues also rose 34% to $302.9 million. Operating income was $101.3 million, up 25%, while net income increased 18% to $97.0 million. The company provided guidance for Q4 revenues of $378-$380 million and fiscal year revenues of $1.446-$1.448 billion. Veeva emphasized ongoing digital transformation in life sciences as a driver of growth.
Veeva Systems (NYSE: VEEV) announced that Bristol Myers Squibb (NYSE: BMY) will adopt Veeva Vault PromoMats for enhanced content delivery across digital channels. This application enables automatic generation of submission-ready forms for products, streamlining the process to meet FDA eCTD requirements. The new capability is expected to launch in December 2020, which will improve compliance and accelerate promotional material packaging for Bristol Myers Squibb. This partnership builds on Veeva's existing solutions, enhancing customer engagement and regulatory compliance.
Veeva Systems (NYSE: VEEV) has expanded its Veeva Link offering to include 11 new therapeutic areas, enhancing real-time customer intelligence for life sciences teams. The new areas cover diverse fields such as cardiology, dermatology, and neurology, building on the success of Veeva Link for Oncology, which is utilized by 6 of the top 10 pharmaceutical companies. The solutions are set to be available in March 2021, leveraging over 50,000 sources for accurate data on healthcare decision-makers.
Veeva Systems (NYSE: VEEV) announced the expansion of Veeva Link to include 11 new therapeutic areas: bacterial infections, cardiology, dermatology, endocrinology, gastroenterology, hepatology, nephrology, neurology, respiratory, rheumatology, and virology. This enhancement aims to provide commercial and medical teams with real-time customer intelligence. Veeva Link is already utilized by six of the ten largest pharmaceutical companies, focusing on improved engagement with healthcare decision-makers. The new solutions are expected to be available in March 2021.
Veeva Systems (NYSE: VEEV) announced that Bristol Myers Squibb (NYSE: BMY) will implement Veeva Vault PromoMats to enhance their promotional material process. This new capability, available in December 2020, allows for automatic generation of submission-ready forms, streamlining the approval process with the U.S. FDA. Vault PromoMats combines digital asset management with regulatory compliance to ensure efficient content distribution. This partnership aims to support Bristol Myers Squibb's needs for faster and compliant content delivery.
Veeva Systems reports that over 75 organizations, including top pharmaceutical companies, are adopting Veeva Vault CTMS to enhance clinical trial efficiency and speed. This modern cloud application is now managing nearly 50,000 clinical trials, facilitating real-time insights and proactive management. The platform integrates with Veeva Vault EDC and includes new capabilities like Vault Payments, allowing for better collaboration and compliance. The focus on streamlining operations aims to mitigate delays and improve overall study execution.
FAQ
What is the current stock price of Veeva Sys (VEEV)?
What is the market cap of Veeva Sys (VEEV)?
